# Chemed Corp (CHE) Stock Analysis: Exploring a 17.39% Potential Upside with Strong Analyst Support

- Link: https://www.directorstalkinterviews.com/chemed-corp-che-stock-analysis-exploring-a-17-39-potential-upside-with-strong-analyst-support/4121240054
- Published: 2026-02-16T11:31:50+00:00
- Author: Madison Wilson

Chemed Corporation (NYSE: CHE) offers a unique proposition in the healthcare sector,
presenting investors with a mix of steady revenue growth and robust operational 
efficiency. With a current market capitalization of $6.9 billion, Chemed stands 
as a significant player in the medical care facilities industry. The company’s impressive
17.39% potential upside, coupled with strong buy ratings, makes it an intriguing
option for investors seeking both growth and stability.

Chemed operates through two primary segments: VITAS, which provides hospice and 
palliative care services, and Roto-Rooter, which offers plumbing and related services.
This dual-segment approach allows Chemed to leverage its expertise across diverse
markets, thereby mitigating sector-specific risks.

###Price and Valuation Metrics###

Currently trading at $473.22, Chemed’s stock price reflects a slight increase of
0.02% from the previous close. The 52-week range of $412.30 to $619.21 illustrates
the stock’s volatility, yet the forward P/E ratio of 18.62 indicates a reasonable
valuation relative to anticipated earnings growth.

Despite the lack of a trailing P/E ratio and other valuation metrics like the PEG
ratio or EV/EBITDA, investors might find solace in the company’s forward-looking
prospects. The average target price of $555.50, as estimated by analysts, suggests
a 17.39% upside potential from the current levels, underpinned by the consensus 
of three buy ratings and one hold rating.

###Performance and Profitability###

Chemed’s revenue growth of 3.10% and an EPS of 18.88 highlight its capacity to generate
profits effectively. The return on equity stands at an impressive 24.11%, signaling
strong management efficiency in utilizing shareholders’ equity to generate earnings.

The company’s free cash flow of approximately $278.54 million illustrates its ability
to reinvest in business operations, maintain liquidity, and potentially increase
shareholder returns through dividends or buybacks. Although the dividend yield is
modest at 0.46%, the low payout ratio of 11.11% indicates room for future increases,
which could attract income-focused investors.

###Analyst Ratings and Technical Indicators###

With no sell ratings from analysts, Chemed has garnered confidence in its strategic
direction and operational execution. The target price range of $475.00 to $595.00
suggests a favorable outlook, placing the average price target well above the current
trading price.

From a technical perspective, the stock’s 50-day moving average of $439.11 indicates
upward momentum, as it trades above the 200-day moving average of $469.28. The Relative
Strength Index (RSI) at 72.52 suggests that the stock might be approaching overbought
territory, yet it also reflects strong investor demand. The Moving Average Convergence
Divergence (MACD) of 6.02, with a signal line at 2.94, further corroborates the 
bullish sentiment.

###Conclusion###

For investors eyeing opportunities in the healthcare sector, Chemed Corporation 
offers a compelling mix of growth potential and financial resilience. The company’s
dual-segment operations provide a diversified revenue base, while its robust cash
flow and high return on equity underscore operational efficiency. With a promising
analyst outlook and substantial potential upside, Chemed is positioned as a strong
candidate for those seeking to capitalize on healthcare trends while benefiting 
from substantial capital appreciation potential.

Share on: